Bioxytran Inc. announced positive results from a recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial of ProLectin-M in subjects with laboratory-confirmed acute viral infection. The study enrolled 38 subjects and evaluated orally administered ProLectin-M over a seven-day treatment period. According to the company, the trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7 compared to placebo (p = .001), with a significant proportion achieving viral non-detection by Day 3. The results were presented by Bioxytran Inc., and the company plans to advance regulatory discussions and pursue late-stage clinical development of ProLectin-M for additional viral indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9652554) on February 11, 2026, and is solely responsible for the information contained therein.